Improving on this, OliX has developed a proprietary linker chemistry ... a phase 1 treatment for both wet and dry age-related macular degeneration (AMD)—the first intraocular RNAi-therapeutic ...

In its ocular franchise, OliX’s OLX301A is in development for both wet and dry age-related macular degeneration (AMD), which can both lead to vision loss. Dry or atrophic AMD is the most common ...

OliX has developed cell penetrating asiRNA (cp-asiRNA), a therapeutic RNAi platform to effectively target diseases including hypertrophic scarring, dry and wet age-related macular degeneration ...